LB1531A. Administration of abatacept, reduces mortality in hospitalized patients with COVID pneumonia. Results of a randomized controlled trial.

BACKGROUND: Severe COVID-19 infection is characterized by a dysregulated hyperinflammatory state that contributes to morbidity and mortality. Immunomodulatory therapy has been shown to improve outcomes. We investigated if abatacept, CTLA-4-Ig, a selective costimulation modulator, provides additional...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, Emily R, Anstrom, Kevin J, Lachiewicz, Anne, Panettieri, Reynold, Maillo, Martin, O'Halloran, Jane A, Boucher, Cynthia, Maldonado, Michael A, Chang, Soju, Bozzette, Samuel, Powderly, William G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752494/
http://dx.doi.org/10.1093/ofid/ofac492.1884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752494/
http://dx.doi.org/10.1093/ofid/ofac492.1884

Ejemplares similares